

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JUNE 10, 2026**

The Board announces that at the AGM held on June 10, 2026, all proposed resolutions as set out in the notice of the AGM were duly passed by the Shareholders by way of poll.

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on June 10, 2026, all proposed resolutions as set out in the notice of the AGM were duly passed by the Shareholders by way of poll. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the circular dated May 19, 2026 (the “**Circular**”). Dr. Zhisheng Chen, Dr. Sherry Xuejun Gu, Mr. William Robert Keller, Mr. Jackson Peter Tai, and Dr. Jue Chen attended the AGM either in person or by electronic means.

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and of the independent auditor of the Company for the year ended December 31, 2025.	2,247,152,905 (99.92%)	1,816,053 (0.08%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
2.	To re-elect the following Directors, each as a separate resolution:		
	(a) To re-elect Dr. Ge Li as non-executive Director.	2,033,928,534 (90.44%)	215,037,417 (9.56%)
	(b) To re-elect Mr. Kenneth Walton Hitchner III as independent non-executive Director.	2,175,266,837 (96.72%)	73,699,114 (3.28%)
	(c) To re-elect Dr. Jue Chen as independent non-executive Director.	2,240,451,265 (99.62%)	8,514,686 (0.38%)
3.	To authorize the Board or any duly authorized board committee to fix the Directors' remuneration for the year ending December 31, 2026.	2,245,809,204 (99.86%)	3,156,747 (0.14%)
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorize the Board or any duly authorized board committee to fix their remuneration.	1,605,242,132 (71.38%)	643,723,819 (28.62%)
5.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company (including any sale or transfer of treasury shares).	2,198,535,567 (97.76%)	50,430,384 (2.24%)
6.	To grant a general mandate to the Directors to repurchase the shares of the Company.	2,247,466,199 (99.93%)	1,499,752 (0.07%)

Notes:

- (1) As at the date of the AGM, (i) the total number of Shares in issue was 4,141,014,517; (ii) there were no treasury Shares held by the Company and (iii) there were 21,096,000 repurchased Shares which are pending cancellation and should be excluded from the total number of Shares in issue for the purpose of the AGM. The Company confirmed that no voting rights of the 21,096,000 repurchased Shares which are pending cancellation have been exercised at the AGM.

Accordingly, the total number of Shares entitling the holders thereof to attend and vote on all the resolutions proposed at the AGM is 4,119,918,517.

- (2) There were no Shares entitling the holders thereof to attend and abstain from voting in favour of any resolution at the AGM as set out in Rule 13.40 of the Listing Rules.

- (3) As at the date of the AGM, Computershare Hong Kong Trustees Limited, being the trustee (the “**Trustee**”) holding unvested Restricted Shares granted under the Restricted Share Award Scheme and/ or the Global Partner Program Share Scheme, held 35,945,795 Shares.

Save for the Trustee who was required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders’ approval under the Listing Rules, no other Shareholder was required to abstain from voting in respect of any resolution at the AGM.

- (4) The Company’s Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

For and on behalf of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, June 10, 2026

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu as executive Directors; Dr. Ge Li, Mr. Yanling Cao and Ms. Jingwen Miao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*